NCT03491683 2026-03-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Inovio Pharmaceuticals
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT06384807 2026-03-11
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Biohaven Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT06412198 2026-03-06
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05125016 2026-02-27
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05882734 2026-02-17
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
EMD Serono
Phase 1/2 Active not recruiting
NCT04913220 2026-02-04
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Sanofi
Phase 1/2 Terminated
NCT04626635 2026-02-02
COMBINE-EGFR-1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT04989946 2026-01-28
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
University of Wisconsin, Madison
Phase 1/2 Recruiting